Locoregional melanoma: identifying optimal care in a rapidly changing landscape

David E Gyorki*1 & Jonathan S Zager2
1Division of Cancer Surgery, Peter MacCallum Cancer Centre & Department of Surgery, University of Melbourne, Melbourne, VIC, 3000 Australia
2Moffitt Cancer Center, Departments of Cutaneous Oncology & Sarcoma, University of South Florida Morsani School of Medicine, Tampa, FL, 33612 USA
*Author for correspondence: Tel.: +61 3 8559 7704; David.gyorki@petermac.org

"highlight the need for a more strategic approach from the melanoma community to study patients with locoregional melanoma independently from patients with more advanced metastatic disease"

First draft submitted: 6 August 2019; Accepted for publication: 14 August 2019; Published online: 28 November 2019

Keywords: melanoma immunotherapy • melanoma research • melanoma systemic therapy

The natural history of patients with cutaneous melanoma can be unpredictable. Most patients will present with an early stage, primary lesion which is managed with curative intent wide surgical excision. For those patients whose disease recurs, the disease course can be highly variable. Some patients, regardless of primary tumor characteristics, will develop rapidly progressive disease which metastasizes widely, whereas others will develop relatively indolent locoregional recurrences over many years or even decades. The latest issue of Melanoma Management presents a number of review papers that describe the current evidence base for clinical decision making for patients with locoregionally advanced melanoma. This in itself is a broad term describing the full spectrum of patients from those with micrometastatic disease in their sentinel lymph node (SLN) to those with unresectable multifocal in-transit metastases.

Currently, there are no biomarkers that can accurately predict the tempo or distribution of disease progression for patients with primary melanoma at the outset. The most reliable prognostic factors for patients undergoing treatment for primary melanoma are a combination of the primary tumor characteristics as well as the status of the SLN which together have allowed the American Joint Committee on Cancer (8th Edition) to create a high-quality evidence-based prognostic framework[1]. For patients with a positive SLN, the last 5 years have seen a dramatic change in the management algorithm. In this issue, Downs et al.[2] describe the findings from two recent large, randomized controlled trials demonstrating no survival benefit to immediate completion lymph node dissection. Interestingly, these new data showing no survival benefit for completion node dissections in the setting of sentinel node positive disease in certain patient populations emerged at the same time as multiple landmark prospective randomized clinical trials demonstrated survival benefit with the use of adjuvant systemic therapies (both immunotherapy with anti-PD-1 inhibitors and targeted therapy with BRAF/MEK inhibition) in the same patient population[3,4]. These practice-changing studies are described in detail by Samuel et al.[5] where the role of adjuvant therapy in patients with resected stage III melanoma is described as a rapidly evolving field and discussed in detail. In recent years, preclinical and clinical data from small series have emerged supporting the use of systemic therapies in a neoadjuvant setting. This approach provides the treating team with an in vivo assessment of clinical response as described by Sun et al.[6]. The authors describe the clinical trials that are currently underway looking at neoadjuvant therapy and the promising preliminary results, allowing for presurgical management of a disease that previously had few options in that arena.

Furthermore, for patients with unresectable locoregional melanoma, a wide variety of regional therapies have demonstrated clinical benefit including intra-arterial therapies, as outlined by Broman et al.[7], and topical and intralesional therapies, documented by Henderson[8]. Both Broman and Henderson discuss innovative minimally
invasive therapies, such as isolated limb infusion, topical dyphencyprone and intralesional oncolytic viral therapy, and their role in the treatment of regionally advanced metastatic melanoma. Although there is clearly compelling data for the efficacy of these therapies, they were largely developed and their evidence base established in the era before effective systemic therapies for melanoma which have revolutionized care over the last decade. The evidence for the use of these therapies, including BRAF and MEK inhibitors as well as checkpoint blockade immunotherapies, for patients with unresectable locoregional melanoma is described by Nan Tie et al. [9]. However, as the authors point out, there is minimal evidence to guide the incorporation of systemic immunotherapies or targeted therapies into current treatment paradigms for unresectable stage III locoregionally metastatic disease. The authors do go on to mention that further evidence is needed to establish the benefit of systemic therapies in the regionally metastatic population.

All of this leaves clinicians managing this patient population with a difficult conundrum as to the optimal management algorithm. Taken together, the review papers in this issue highlight the need for a more strategic approach from the melanoma community to study patients with locoregional melanoma independently from patients with more advanced metastatic disease. It remains unclear which patients should receive locoregional therapies as first line and which patients would benefit from systemic therapy upfront. Or, even whether some patients should receive combinations of these. Quality of life and health economic implications also need to be considered given the increasing cost of care and the aging population.

Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Open access
This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/

References
1. Gershenwald JE, Scolyer RA, Hess KR et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J. Clin. 67(6), 472–492 (2017).
2. Downs J, Gyorki DE. An evidence-based approach to positive sentinel node disease: should we ever do a completion node dissection? Melanoma Manag. 6(3), MMT24 (2019).
3. Weber J, Mandala M, Del Vecchio M et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N. Engl. J. Med. 377, 1824–1835 (2017).
4. Long GV, Hauschild A, Santinami M et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N. Engl. J. Med. 377, 1813–1823 (2017).
5. Samuel E, Moore M, Voskoboynik M, Shackleton M, Haydon A. An update on adjuvant systemic therapies in melanoma. Melanoma Manag. 6(3), MMT27 (2019).
6. Sun J, Kirichenko D, Zager S, Eroglu Z. The emergence of neoadjuvant therapy in metastatic melanoma. Melanoma Manag. 6(3), MMT22 (2019).
7. Broman K, Zager J. Intra-arterial perfusion based therapies for regionally metastatic cutaneous and uveal melanoma. Melanoma Manag. 6(3), MMT26 (2019).
8. Henderson M. Topical and intralesional therapies for in-transit melanoma. Melanoma Manag. 6(3), MMT23 (2019).
9. Nan Tie E, Lai-Kwon J, Gyorki DE. Systemic therapies for unresectable locoregional melanoma: a significant area of need. Melanoma Manag. 6(3), MMT25 (2019).
